Back to Supplement Finder

BioZapetite x 90 Vegetable Capsules

Sold by FMI Health

INR 27,984.00

View at FMI Health
Store
fmihealth.com
Brand
Biolongevity Labs
Collected
2026-11-20

From the retailer

Retailer description retrieved 2026-11-20. Claims are the retailer’s, not independently verified.

Description--BioZapetite - Oral GLP-1 Receptor Agonist Research Compound (6 mg)

 

BioZapetite delivers orforglipron (6 mg), a first-in-class oral, small-molecule GLP-1 receptor agonist. Unlike peptide-based GLP-1 agonists, orforglipron is orally bioavailable without fasting or water restrictions and demonstrates robust pharmacology in glucose regulation, weight reduction, and cardiometabolic health.

 

Mechanistic Claims

  • Glucose Disposal & Insulin Sensitivity
    • Enhances glucose-dependent insulin secretion.
    • Suppresses glucagon release.
    • Improves post-prandial glucose control.
  • Weight Reduction & Appetite Control
    • Activates central satiety signaling pathways.
    • Slows gastric emptying.
    • Consistently reduces caloric intake.
  • Lipid & Cardiometabolic Health
    • Secondary benefits of weight loss include reductions in blood pressure, triglycerides, and waist circumference.
  • Oral Dosing Convenience
    • Half-life of ~29–49 hours supports once-daily dosing.
    • No need for co-formulated absorption enhancers.
  • Safety Profile
    • Consistent with injectable GLP-1 agonists.
    • Predominantly mild-to-moderate GI events during titration.
    • No hepatic safety signal observed in Phase 3 readouts.

 

Research Applications

  • Appetite regulation and body weight studies
  • Glucose disposal and glycemic control investigations
  • Cardiometabolic risk reduction models
  • Oral small-molecule incretin pharmacology
  • Translational safety and GI tolerability research


Research Insights

 

Glucose Disposal & Glycemic Control

In a 26-week multicentre trial in type 2 diabetes (n=383), orforglipron reduced HbA1c up to –2.10% and body weight by –10.1 kg, significantly outperforming placebo and matching/exceeding dulaglutide at higher doses [3]. A 12-week Phase 1b trial reported HbA1c reductions of –1.5% to –1.8% with up to –5.8 kg weight loss [4].

 

Appetite & Weight Regulation

In a 36-week obesity study, orforglipron produced –9.4% to –14.7% weight reduction vs –2.3% with placebo, with 46–75% of participants achieving ≥10% weight loss depending on dose [1][2]. Improvements were observed in all prespecified cardiometabolic measures, including waist circumference, blood pressure, and lipid markers.

 

Oral Pharmacology & PK

Unlike oral peptide GLP-1 formulations, orforglipron does not require an absorption enhancer

 

Safety & Tolerability

Across Phase 2 and Phase 3 programs, the safety profile was consistent with injectable GLP-1 RAs. GI events (nausea, diarrhea, dyspepsia, vomiting) were most common and dose-related, occurring mainly during titration [3][5]. In Phase 3 (ACHIEVE-1), discontinuations due to AEs were 4–8% vs 1% with placebo, and no hepatic safety signals were detected [5].

 

References


Label--

Supplement Facts
Serving Size: 1 Capsule
Servings per Container: 90
Ingredient Amount Per Serving
Orforglipron


Dosage--For Research Purposes Only